摘要
There is a worldwide increase in the annual incidence of intrahepatic cholangiocarcinoma(iCCA)(1).For this reason,the review from Bupathi et al.assesses a highly relevant topic.Their work shows several important advances in the management of iCCA in the past few decades(2).They review the role of adjuvant therapy for patients with early stages and adverse prognostic factors(i.e.,lymph nodal disease).Also,they report recent achievements in the management of advanced disease.Despite the progress made in the management of iCCA,much is still to be done.
